Metformin and Cancer, an Ambiguanidous Relationship

Area of Science:

• Oncology
• Metabolic Research
• Pharmacology

Background:

• Cancer cells exhibit altered energetic and cellular metabolism.
• Metformin, a common diabetes medication, has demonstrated potential anticancer effects in various cancer types.
• The precise mechanisms by which metformin impacts cancer cell metabolism and growth are not fully understood.

Purpose of the Study:

• To review the role of metformin as an antitumoral agent.
• To detail evidence on the potential use and mechanisms of action of metformin in cancer.
• To explore the antitumoral, signaling, and metabolic impacts of metformin on cancer cells.

Main Methods:

• Literature review of existing studies on metformin and cancer.
• Analysis of metformin's effects on cancer cell signaling pathways.
• Examination of metformin's impact on cancer cell metabolism.

Main Results:

• Metformin is recognized as an adenosine monophosphate-activated protein kinase (AMPK) agonist and an inhibitor of the electron transport chain complex I.
• Evidence suggests metformin can inhibit cell growth in pancreatic, colon, prostate, ovarian, and breast cancers.
• The specific molecular targets and metabolic pathways affected by metformin in cancer cells require further elucidation.

Conclusions:

• Metformin exhibits antitumoral properties, making it a potential therapeutic agent in oncology.
• Understanding metformin's detailed mechanisms of action in cancer is crucial for developing novel therapeutic strategies.
• Targeting cancer cell metabolism with agents like metformin offers promising avenues for cancer treatment.